189 related articles for article (PubMed ID: 27471692)
1. Therapeutic vaccines in non-small cell lung cancer.
Socola F; Scherfenberg N; Raez LE
Immunotargets Ther; 2013; 2():115-24. PubMed ID: 27471692
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
Ruiz R; Hunis B; Raez LE
Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
[TBL] [Abstract][Full Text] [Related]
3. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
Perez CA; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
[TBL] [Abstract][Full Text] [Related]
4. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
Mellstedt H; Vansteenkiste J; Thatcher N
Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
[TBL] [Abstract][Full Text] [Related]
5. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
Decoster L; Wauters I; Vansteenkiste JF
Ann Oncol; 2012 Jun; 23(6):1387-93. PubMed ID: 22156658
[TBL] [Abstract][Full Text] [Related]
6. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for lung cancer: ongoing clinical trials.
Declerck S; Vansteenkiste J
Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in immunotherapy for non-small-cell lung cancer.
Suzuki H; Owada Y; Watanabe Y; Inoue T; Fukuharav M; Yamaura T; Mutoh S; Okabe N; Yaginuma H; Hasegawa T; Yonechi A; Ohsugi J; Hoshino M; Higuchi M; Shio Y; Gotoh M
Hum Vaccin Immunother; 2014; 10(2):352-7. PubMed ID: 24196313
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
[TBL] [Abstract][Full Text] [Related]
10. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in lung cancer.
Villaruz LC; Kalyan A; Zarour H; Socinski MA
Transl Lung Cancer Res; 2014 Feb; 3(1):2-14. PubMed ID: 25806276
[TBL] [Abstract][Full Text] [Related]
12. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
[TBL] [Abstract][Full Text] [Related]
13. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
14. Vaccination therapy for non-small-cell lung cancer.
Cuppens K; Vansteenkiste J
Curr Opin Oncol; 2014 Mar; 26(2):165-70. PubMed ID: 24441502
[TBL] [Abstract][Full Text] [Related]
15. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
[TBL] [Abstract][Full Text] [Related]
16. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
[TBL] [Abstract][Full Text] [Related]
17. Why has active immunotherapy not worked in lung cancer?
Thomas A; Giaccone G
Ann Oncol; 2015 Nov; 26(11):2213-20. PubMed ID: 26232492
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
[TBL] [Abstract][Full Text] [Related]
19. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
Saavedra D; Crombet T
Front Immunol; 2017; 8():269. PubMed ID: 28348561
[TBL] [Abstract][Full Text] [Related]
20. Belagenpumatucel-L for the treatment of non-small cell lung cancer.
Rijavec E; Biello F; Genova C; Barletta G; Maggioni C; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Beltramini S; Grassi MA; Boccardo F; Grossi F
Expert Opin Biol Ther; 2015; 15(9):1371-9. PubMed ID: 26211534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]